JY
RUBY

Jeff Yass’s Rubius Therapeutics, Inc RUBY Stock Holding History

Jeff Yass’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-96,985
Closed -$42K – 14287
2022
Q3 		$42K Buy
96,985
+50,855
+110% +$38.1K ﹤0.01% 12312
2022
Q2 		$39K Sell
46,130
-25,682
-36% -$43.1K ﹤0.01% 12113
2022
Q1 		$396K Sell
71,812
-17,067
-19% -$108K ﹤0.01% 9570
2021
Q4 		$860K Buy
88,879
+44,450
+100% +$616K ﹤0.01% 7694
2021
Q3 		$794K Buy
44,429
+12,043
+37% +$262K ﹤0.01% 8156
2021
Q2 		$791K Buy
+32,386
New +$810K ﹤0.01% 8408
2021
Q1 		– Sell
-24,349
Closed -$356K – 13038
2020
Q4 		$185K Buy
+24,349
New +$145K ﹤0.01% 10097
2020
Q3 		– Sell
-14,128
Closed -$84K – 11350
2020
Q2 		$84K Sell
14,128
-4,448
-24% -$26.3K ﹤0.01% 9577
2020
Q1 		$83K Buy
+18,576
New +$138K ﹤0.01% 9435
2019
Q4 		– Sell
-16,656
Closed -$131K – 10933
2019
Q3 		$131K Buy
16,656
+1,906
+13% +$22.2K ﹤0.01% 9409
2019
Q2 		$232K Buy
+14,750
New +$238K ﹤0.01% 8838

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's RUBY Position: Q4 2022 in Review

Jeff Yass sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 96,985 shares — an estimated $42K sold.

Jeff Yass first reported a position in RUBY in Q2 2019 and held it in 11 quarters. The position peaked at $860K in Q4 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Jeff Yass reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Jeff Yass sold 96,985 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $42K.
  • Jeff Yass first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 11 quarters.
  • Jeff Yass's Rubius Therapeutics, Inc position peaked at $860K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.